Kathy Cai, MD, PhD
Associate Research Professor
Co-Director, Histopathology Facility
My research interest focuses on developing and improving histopathology-related technologies to support basic and translational research projects involving cell signaling, molecular carcinogenesis and animal modeling. These approaches include immunohistochemistry, quantitative image analysis using Aperio technology and AQUA (a automatic quantitation platform for immunohistochemistry), laser capture microdissection, and other technologies. With these cutting-edge technologies, I have been working closely with other investigators, supporting their projects by providing histopathological evaluations and IHC marker quantifications.
My long-term research interests include understanding the molecular mechanism of ovarian cancer initiation and development. Research projects completed or in progress include quantitative image analysis of biomarkers on ovarian cancer tissue microarrays, molecular characterization of initiation and progression of ovarian cancer, mouse modeling of ovarian cancer, and studies of early mouse embryonic development.
In my capacity as co-director of the Histopathology Facility, I support Cancer Center members in interpreting results from tissues derived from animal models of human cancer. The rodent models in which I work or have worked include ovarian cancer, mesothelioma, kidney cancer and polycystic disease, pancreatic cancer, and lung cancer and lymphoma.
- PhD, Fudan University, China, 2002
- MD, Shanghai Medical University, China, 1994
- Development and improvement of immunohistochemical (IHC, traditional and fluorescence-based) assays to detect and quantify important components of cell signaling pathways
- Molecular mechanism of ovarian cancer initiation and development
- Histopathology evaluation of rodent models of human cancer
Li, H., Cai, Q., Wu, H., Vathipadiekal, V., Dobbin, Z.C., Li, T., Hua, X., Landen, C.N., Birrer, M.J., Sánchez-Beato, M., Zhang, R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol. Cancer Res. 10:1462-1472, 2012. PMCID: PMC3501543
Cai, K.Q., Caslini, C., Capo-chichi, C.D., Slater, C, Smith, E.R., Wu, H., Klein-Szanto, A., Godwin, A.K., Xu, X. Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS ONE 4(7):e6454, 2009. PMC2715102 PubMed
Capo-chichi, C.D., Cai, K.Q., Testa, J.R., Godwin, A.K., Xu, X.X. Loss of GATA6 leads to nuclear deformation and aneuploidy in ovarian cancer. Mol. Cell. Biol. 29:4766-4777, 2009. PMC2725711 PubMed
Cai, K.Q., Wu, H., Klein-Szanto, A.J., Xu, X.X. Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity. Gynecol. Oncol. 114:18-25, 2009. PMC2739736 PubMed
Cai, K.Q., Capo-Chichi, C.D., Rula, M.E., Yang, D.H., Xu, X.X. Dynamic GATA6 expression in primitive endoderm formation and maturation in early mouse embryogenesis. Dev. Dyn. 237:2820-2829, 2008. PMC2739724 PubMed
Rula, M.E.*, Cai, K.Q.*, Moore, R., Yang, D.H., Staub, C.M., Capo-Chichi, C.D., Jablonski S.A., Howe, P.H., Smith, E.R., Xu, X.X. Cell autonomous sorting and surface positioning in the formation of primitive endoderm in mouse blastocysts and embryoid bodies. Genesis 45:327-338, 2007. *Co-first authors. PubMed Collapse
The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.
Share with Facebook
Share with twitter
Share with email